SFI
NVNO

Susquehanna Fundamental Investments’s enVVeno Medical NVNO Stock Holding History

Susquehanna Fundamental Investments’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-453
Closed -$164K – 1671
2021
Q3 		$164K Buy
+453
New +$117K ﹤0.01% 1565

Other funds holding NVNO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

Susquehanna Fundamental Investments's NVNO Position: Q4 2021 in Review

Susquehanna Fundamental Investments sold out of enVVeno Medical (NVNO) in Q4 2021, closing a stake of 453 shares — an estimated $164K sold.

Susquehanna Fundamental Investments first reported a position in NVNO in Q3 2021 and held it in 1 quarter. The position peaked at $164K in Q3 2021. 24 funds tracked by Wall St. Rank hold NVNO as of Q4 2021.

  • Susquehanna Fundamental Investments reported no remaining enVVeno Medical position as of Q4 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 453 enVVeno Medical shares in Q4 2021, an estimated $164K.
  • Susquehanna Fundamental Investments first reported a position in enVVeno Medical in Q3 2021 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's enVVeno Medical position peaked at $164K in Q3 2021.
  • 24 funds tracked by Wall St. Rank held enVVeno Medical as of Q4 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2021, filed 14 Feb 2022.